Signatera detects molecular residual disease in bladder cancer by identifying tumor DNA fragments in the bloodstream, even when not visible on scans. The IMvigor010 trial showed that Signatera-guided ...
TAR-200, a small drug-releasing implant, wiped out tumors in most patients with high-risk bladder cancer. Its slow, consistent release of chemotherapy proved far more effective than traditional ...
2025 DEC 31 (NewsRx) -- By a News Reporter-Staff News Editor at Insurance Daily News-- Current study results on Managed Care have been published. According to news reporting out of San Francisco, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback